Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial Novo Nordisk today announced…
Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced the U.S. Food and Drug Administration (FDA) approved ZURZUVAE™ (zuranolone) 50 mg for adults with postpartum depression (PPD). ZURZUVAE is the…
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder Biogen Inc. (Nasdaq: BIIB) and Sage…
AI drives a new era of target identification and drug design Disease modeling and target identification are critical and time-consuming portions of the drug discovery process and areas where artificial…
Learning how to control HIV from African genomes Despite significant advances in treatment and access to therapy, the human immunodeficiency virus remains a global health challenge with almost 40 million…
New RNA-based therapy combats melanoma in mouse models Investigators at the Icahn School of Medicine at Mount Sinai have designed an innovative RNA-based strategy to activate dendritic cells – which…
Johnson & Johnson Subsidiary to Appeal Bankruptcy Court Ruling that Deprived Talc Claimants of an Equitable and Efficient Resolution Johnson & Johnson (NYSE: JNJ) (the Company) today announced its subsidiary…
AstraZeneca appoints Sharon Barr as Executive Vice President BioPharmaceuticals R&D AstraZeneca today announced the appointment of Sharon Barr as Executive Vice President, BioPharmaceuticals R&D. Sharon will succeed Mene Pangalos, who…
Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer Merck (NYSE: MRK), known as MSD outside…
Pfizer Announces Executive Leadership to Advance Oncology Research and Development Strategy Pfizer Inc. (NYSE: PFE) today announced changes to its executive leadership team to further advance its aspirations to discover and…
Enhertu demonstrated clinically meaningful progression-free survival and overall survival across multiple HER2-expressing advanced solid tumors in DESTINY-PanTumor02 Phase II trial High-level results from the primary analysis of the ongoing DESTINY-PanTumor02…
MERCK AND MODERNA INITIATE PHASE 3 STUDY EVALUATING V940 (MRNA-4157) IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) FOR ADJUVANT TREATMENT OF PATIENTS WITH RESECTED HIGH-RISK (STAGE IIB-IV) MELANOMA Merck (NYSE: MRK), known…